90.98
1.11 (1.24%)
| Previous Close | 89.86 |
| Open | 90.03 |
| Volume | 54,032 |
| Avg. Volume (3M) | 1,005,962 |
| Market Cap | 5,217,416,192 |
| Price / Earnings (Forward) | 1.43 |
| Price / Sales | 10.45 |
| Price / Book | 6.04 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Glaukos Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.90 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 134.00 (UBS, 47.29%) | Buy |
| Median | 118.00 (29.71%) | |
| Low | 92.00 (Wells Fargo, 1.13%) | Hold |
| Average | 114.67 (26.05%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 86.57 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 10 Sep 2025 | 118.00 (29.71%) | Buy | 87.52 |
| UBS | 31 Jul 2025 | 134.00 (47.29%) | Buy | 86.09 |
| Wells Fargo | 31 Jul 2025 | 92.00 (1.13%) | Hold | 86.09 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NAVRATIL TOMAS | - | 87.47 | -5,142 | -449,771 |
| Aggregate Net Quantity | -5,142 | |||
| Aggregate Net Value ($) | -449,771 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 87.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NAVRATIL TOMAS | Officer | 11 Sep 2025 | Automatic sell (-) | 5,142 | 87.47 | 449,771 |
| Date | Type | Details |
|---|---|---|
| 13 Aug 2025 | Announcement | Glaukos Announces Participation in Wells Fargo Healthcare Conference |
| 30 Jul 2025 | Announcement | Glaukos Announces Second Quarter 2025 Financial Results |
| 09 Jul 2025 | Announcement | Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 |
| 25 Jun 2025 | Announcement | Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell |
| 25 Jun 2025 | Announcement | Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |